Income StatementBalance SheetCash FlowSegments
MAN

Veradermics Cash Flow Statement

Operating, investing, and financing cash movements
Net Cash From Operating-$21.2MNet Cash From Investing-$101.3MNet Cash From Financing$269.1MCapital Expenditures-Net Change In Cash$146.6M
Market Cap$4.4B

Investing

MetricQ1 '25Q1 '26
Capital expenditures$19.0K$0.0
Net cash from investing activities-$15.8M-$101.3M
Purchases of investments$15.7M$123.0M
Proceeds From Sale And Maturity Of Available For Sale Securities$0.0$21.7M

Operating

MetricQ1 '25Q1 '26
Change in accounts payable-$686.0K-$1.1M
Change in accrued liabilities-$862.0K-$1.4M
Change in other assets$0.0$174.0K
Change in other liabilities-$7.0K-$8.0K
Net cash from operating activities-$13.3M-$21.2M
Net income-$12.4M-$27.2M
Stock-based compensation$213.0K$5.3M
Accretion (Amortization) of Discounts and Premiums, Investments$13.0K$73.0K
Increase (Decrease) in Accrued Interest Receivable, Net$0.0$1.5M
Increase (Decrease) in Prepaid Expense and Other Assets-$79.0K-$4.4M
Other Noncash Income (Expense)-$2.0K-$6.0K
Non-cash research and development services$357.0K$621.0K

Free Cash Flow

MetricQ1 '25Q1 '26
Free cash flow-$13.3M-$21.2M

Financing

MetricQ1 '25Q1 '26
Net cash from financing activities$8.4M$269.1M
Proceeds from issuance of preferred stock$8.4M$0.0
Proceeds from issuance of common stock$0.0$11.0K
Net proceeds from sales of subsidiary shares$0.0$269.1M

Other

MetricQ1 '25Q1 '26
Net increase (decrease) in cash-$20.6M$146.6M
Unrealized loss on marketable securities$0.0-$584.0K
Leased assets obtained in exchange for operating lease liabilities$90.0K$0.0